Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
一名患有炎性肌纤维母细胞瘤的患者，在克唑替尼治疗进展后，对色瑞替尼治疗有反应，该患者存在TPM3-ALK重排。
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw405
Mansfield, A S; Murphy, S J; Harris, F R; Robinson, S I; Marks, R S; Johnson, S H; Smadbeck, J B; Halling, G C; Yi, E S; Wigle, D; Vasmatzis, G; Jen, J
